Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?

Crystal R. Leibrand; Douglas K. Price; William D. Figg

doi:10.1080/15384047.2016.1156274

Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?

Crystal R. Leibrand, Douglas K. Price, William D. Figg^*

^*Corresponding author for this work

Surgery

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Currently there are no molecular biomarkers used to help guide treatment selection for those patients with castration-resistant prostate cancer. A recent study published in JAMA Oncology (Antonarakis et al.) presents evidence supporting the potential use of androgen receptor splice variant 7 as a biomarker for optimal treatment selection in this population.

Original language	English
Pages (from-to)	467-469
Number of pages	3
Journal	Cancer Biology and Therapy
Volume	17
Issue number	5
DOIs	https://doi.org/10.1080/15384047.2016.1156274
State	Published - 3 May 2016

Keywords

Androgen receptor; prostate cancer; splice variants

Access to Document

10.1080/15384047.2016.1156274

Cite this

@article{6ec5958e254c40daa7ee0600eef0d900,

title = "Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?",

abstract = "Currently there are no molecular biomarkers used to help guide treatment selection for those patients with castration-resistant prostate cancer. A recent study published in JAMA Oncology (Antonarakis et al.) presents evidence supporting the potential use of androgen receptor splice variant 7 as a biomarker for optimal treatment selection in this population.",

keywords = "Androgen receptor; prostate cancer; splice variants",

author = "Leibrand, {Crystal R.} and Price, {Douglas K.} and Figg, {William D.}",

note = "Publisher Copyright: {\textcopyright} 2016 Taylor & Francis Group, LLC.",

year = "2016",

month = may,

day = "3",

doi = "10.1080/15384047.2016.1156274",

language = "English",

volume = "17",

pages = "467--469",

journal = "Cancer Biology and Therapy",

issn = "1538-4047",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer

T2 - Biomarker for treatment selection exclusion or inclusion?

AU - Leibrand, Crystal R.

AU - Price, Douglas K.

AU - Figg, William D.

PY - 2016/5/3

Y1 - 2016/5/3

N2 - Currently there are no molecular biomarkers used to help guide treatment selection for those patients with castration-resistant prostate cancer. A recent study published in JAMA Oncology (Antonarakis et al.) presents evidence supporting the potential use of androgen receptor splice variant 7 as a biomarker for optimal treatment selection in this population.

AB - Currently there are no molecular biomarkers used to help guide treatment selection for those patients with castration-resistant prostate cancer. A recent study published in JAMA Oncology (Antonarakis et al.) presents evidence supporting the potential use of androgen receptor splice variant 7 as a biomarker for optimal treatment selection in this population.

KW - Androgen receptor; prostate cancer; splice variants

UR - http://www.scopus.com/inward/record.url?scp=84963603681&partnerID=8YFLogxK

U2 - 10.1080/15384047.2016.1156274

DO - 10.1080/15384047.2016.1156274

M3 - Article

C2 - 26985596

AN - SCOPUS:84963603681

SN - 1538-4047

VL - 17

SP - 467

EP - 469

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

IS - 5

ER -

Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?

Abstract

Keywords

Access to Document

Fingerprint

Cite this